JAMA Oncol:改善癌症患者生存率 健康保险功不可没

2018-05-10 吴星 环球医学

2018年3月,美国科学家在《JAMA Oncol》发表了加利福尼亚1997~2014年不同健康保险状态患者的癌症存活率趋势。

2018年3月,美国科学家在《JAMA Oncol》发表了加利福尼亚1997~2014年不同健康保险状态患者的癌症存活率趋势。

重要性:在美国,癌症早期检测、治疗和生存期已有大幅改善,但尚不清楚不同类型健康保险的患者能从这些进展中获得何种程度的受益。

目的:旨在考察1997年1月~2014年12月,不同健康保险状态的癌症存活率趋势。

设计、地点和参与者:加利福尼亚癌症注册(一个州级癌症监测系统)数据用于评估以下三个阶段的不同健康保险状态的基于人群的生存率:1997年1月~2002年12月,2003年1月~2008年12月,2009年1月~2014年12月,随访至2014年。总体来说,确诊为乳腺癌、前列腺癌、结直肠癌肺癌或黑色素瘤的1149891例加利福尼亚患者纳入到研究中。

主要结局和测量指标:每个癌症部位和性别的不同保险类别和时间段的5年全因和癌症特异的生存概率;每个时间段中,每种保险类别(无、Medicare或其他公共医保)vs私人保险的风险比(HRs)及95%置信区间(CIs)。

结果:根据加利福尼亚癌症注册中1149891例确诊为乳腺癌、前列腺癌、结直肠癌、肺癌或黑色素瘤的患者的数据,存活率的改善几乎仅限于具有私人或Medicare的患者。对于具有其他公共保险或无保险的患者,生存率多未改变或下降。相对于私人保险患者,未保险患者除了前列腺癌外,其他所有癌症类型的癌症特异性死亡率较高,乳腺癌(HR,1.72;95% CI,1.45~2.03)、肺癌(男性:HR,1.18;95% CI,1.06~1.31;女性:HR,1.32;95% CI,1.15~1.50)、结直肠癌(女性:HR,1.30;95% CI,1.05~1.62)的2009~2014年的差异最大。具有其他公共保险的患者,除了肺癌外的所有癌症的死亡率也较高,乳腺癌(HR,1.25;95% CI,1.17~1.34)、前列腺癌(HR,1.17;95% CI,1.04~1.31)和结直肠癌(男性:HR,1.16;95% CI,1.08~1.23;女性:HR,1.11;95% CI,1.03~1.20)2009~2014年的差异最大。

结论和意义:考虑了患者和临床特征后,前列腺癌男性和肺癌或结直肠癌女性的生存差异随时间显着增加,反映了其他公共保险或无保险患者的生存结局缺乏改善。为了消除这些日益增长的差距,根据临床指南,所有癌症患者都要获得覆盖所有必要医疗保健要素(从预防和早期检测到及时治疗)的健康保险。

原始出处:

Ellis L, et al. Trends in Cancer Survival by Health Insurance Status in California From 1997 to 2014. JAMA Oncol. 2018 Mar 1;4(3):317-323. doi: 10.1001/jamaoncol.2017.3846.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-06-26 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-13 guicaiwei

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-12 guicaiwei

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-12 feifers
  8. [GetPortalCommentsPageByObjectIdResponse(id=1932625, encodeId=a3561932625a6, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Jan 29 13:19:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865436, encodeId=f64d1865436fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Jun 26 00:19:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314704, encodeId=680e314e0428, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sun May 13 09:09:31 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314490, encodeId=a42c31449090, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BHHqJOYCGO2Qnoy0HvW6a8484LMTViaaTLQricqaDrrg5shY907vventGeHZZgj5mlobGntCxX1JqYBgoEhLePCw/132, createdBy=a4312343135, createdName=guicaiwei, createdTime=Sat May 12 18:44:14 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256653, encodeId=01d81256653f7, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289599, encodeId=aa7d1289599d9, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599570, encodeId=ee5615995e0a9, content=<a href='/topic/show?id=31992e25482' target=_blank style='color:#2F92EE;'>#保险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27254, encryptionId=31992e25482, topicName=保险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db9918732976, createdName=feifers, createdTime=Sat May 12 10:19:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313879, encodeId=1a483138e9d3, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu May 10 19:22:58 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 惠映实验室

    学习了.谢谢分享.

    0

相关资讯

Open Biol:癌细胞如何在营养不良的状况下生长繁殖?

癌症研究领域的其中一个秘密就是肿瘤细胞如何在血液和营养状况不良的情况下存活并且生长,近日,来自弗林德斯大学和纽卡斯尔大学的科学家们通过研究系统性地绘制了相关的核心基因图谱和生物学图谱来解释癌细胞如何在营养压力状况下得以生存并繁殖,相关研究刊登于国际杂志Open Biology上。

真的!维生素D可以帮你远离癌症风险

通常在我们的印象中,维生素D只与钙代谢以及骨骼健康密切相关。也许我们只会在人缺钙的时候才会想到去补充维生素D。但是你肯定想不到,血浆中维生素D水平的高低也与恶性肿瘤,特别是肝癌发生风险呈负相关。目前最新的体外研究和动物实验中已经证实,维生素D可以通过多种信号通路,比如细胞周期阻滞、细胞凋亡、血管生成和炎症抑制等多种信号通路抑制肿瘤的发生和发展。最近日本研究者,通过一项涉及14万人近20年的前瞻性队

降低 50% 进展风险,联合疗法获批治疗血液癌症

今日,总部位于丹麦哥本哈根的 Genmab 和强生旗下杨森(Janssen)公司宣布,美国 FDA 已批准其新药 DARZALEX®(daratumumab)联合 VELCADE®(bortezomib,一种蛋白酶体抑制剂 [PI])、美法仑(melphalan)和强的松(prednisone)(VMP),用于治疗不适合自体干细胞移植(ASCT)的新诊断多发性骨髓瘤患者。

严重心衰5年生存率比癌症更低,专家呼吁加强认识和综合治疗

“近30年来,我国心衰的治疗情况已经有了很大改善,死亡率下降了60%-80%。但即便这样,严重心衰5年生存率甚至比恶性肿瘤更低。”上海市浦东新区浦南医院心血管内科主任于泓教授表示。为让浦东基层及二三级医院医护人员及时了解“心衰”领域诊治新进展,由于泓教授发起的“2018年浦南医院心衰综合治疗学习班”日前在浦东新区成功举办。学习班邀请沪上及日本知名心血管领域专家参与。于泓教授说,目前临床治疗心衰的

从10毫升血液中捕捉癌症突变!

有文献报道,晚期肺癌患者中有10%—15%的比例由于受到各种客观原因限制,无法进行穿刺活检,从而导致在对一代靶向药物产生耐药性后无法通过组织活检寻找后续治疗方案,这让患者身陷绝望的境地。不过现在只要采集10毫升的血液,就可以通过“液态活检”这一新型检测手段为这些患者找到出路,而这项技术也可用于其他癌症的监测治疗。

J Biol Chem:糖代谢VS脂代谢,科学家找到了癌症代谢新联系

上海交通大学医学院和Albert Einstein医学院的研究人员发现了一种使肿瘤细胞迅速增殖的酶,抑制这种酶可能是缓解癌症生长的潜在策略。这项研究发表于著名学术期刊《Journal of Biological Chemistry》。